Injected antibodies provide long-term protection against HIV

Trial results show extended protection against HIV in monkeys treated with monoclonal antibodies.

Use of antiretroviral therapy could contribute to a reduction in HIV virulence at the population level, study finds

So far, little progress has been made in generating an effective vaccine against HIV. An alternative approach is the prophylactic administration of monoclonal antibodies (mAbs) against the virus, a strategy used against hepatitis A before a vaccine was available. 

Researchers explored the efficacy of four anti-HIV neutralising mAbs in 24 monkeys. After receiving the mAb infusion, the animals were challenged weekly with a low dose of a chimeric simian/HIV. 

The researchers found that mAb administration extended the median time to infection by between 8 and 13 weeks, compared with a median of 3 weeks among control animals. One treated monkey was protected for 23 weeks. 

Reporting in Nature (online, 27 April 2016)[1]
, the team says that the use of anti-HIV mAbs in areas where the virus is endemic could have a major impact on transmission.


[1] Gautam R, Nishimura Y, Pegu A et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 2016. doi: 10.1038/nature17677

Last updated
Clinical Pharmacist, CP, June 2016, Vol 8, No 6;8(6):DOI:10.1211/PJ.2016.20201124

You may also be interested in